Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciclesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 11/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.59 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | IL5 | P05113 | 1/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciclesonide SCHEMBL15830978 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL1753411 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL4782166 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL14493775 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL1244607 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL13575757 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL17439183 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL13014882 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL5700709 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL139353 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 24325 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102485-A1 | PRODUCTS AND METHODS FOR THE ASSESSMENT AND TREATMENT OF SEPSIS AND IMMUNOLOGICAL AND INFLAMMATORY CONDITIONS | CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC (AU) | 2026-05-21 | — | — | WO | claimed |
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739294-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| EP-4739295-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| CN-117064869-B | Capsule type inhalation powder spray and preparation method thereof | 山东京卫制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260125686-A1 | COMPOSITIONS AND METHODS FOR MODULATION OF CFTR | CYSTIC FIBROSIS FOUND (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| CN-1293572-A | Method and means for treating glomerulonephritis | PHARMALINK BASLUEMEDEL AB (SE) | 2001-05-02 | — | — | CN | claimed |
| WO-2001028562-A1 | CICLESONIDE CONTAINED PHARMACEUTICAL COMPOSITION FOR APPLICATION TO MUCOSA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-04-26 | — | — | WO | claimed |
| WO-2001028563-A1 | CICLESONIDE-CONTAINING AQUEOUS PHARMACEUTICAL COMPOSITION | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-04-26 | — | — | WO | claimed |
| EP-1056461-A1 | METHOD AND MEANS FOR TREATING GLOMERULONEPHRITIS | Pharmalink AB (SE) | 2000-12-06 | — | — | EP | claimed |
| WO-2000030608-A1 | PRESSURISED METERED DOSE INHALERS (MDI) | CHIESI FARMACEUTICI S.P.A. (IT) | 2000-06-02 | — | — | WO | claimed |
| EP-0983058-A1 | MEDICINAL AEROSOL PRODUCTS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-03-08 | — | — | EP | claimed |
| US-6030604-A | Formulation for inhalation | ASTRA AKTIEBOLAG (SE) | 2000-02-29 | — | — | US | claimed |
| WO-1999047144-A1 | METHOD AND MEANS FOR TREATING GLOMERULONEPHRITIS | PHARMALINK BASLÄKEMEDEL AB (SE) | 1999-09-23 | — | — | WO | claimed |
| US-5891844-A | INFANT OR ADULT RESPIRATORY DISTRESS SYNDRONE; SYNERGISTIC MIXTURE OF GLUCOCORTICOSTEROID AND LUNG SURFACTANT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-04-06 | — | — | US | claimed |
| WO-1998052542-A1 | MEDICINAL AEROSOL PRODUCTS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-11-26 | — | — | WO | claimed |